Skip to main content
Rapid Dose Therapeutics Corp logo

Rapid Dose Therapeutics Corp — Investor Relations & Filings

Ticker · DOSE ISIN · CA75339A1012 CSE Manufacturing
Open in API
Filings indexed 490 across all filing types
Latest filing 2023-02-10 Capital/Financing Update
Country CA Canada
Listing CSE DOSE

About Rapid Dose Therapeutics Corp

https://rapid-dose.com/

Rapid Dose Therapeutics Corp. is a pharma-technology company specializing in proprietary drug delivery technologies engineered to enhance patient outcomes and quality of life. The core business revolves around an innovative oral delivery platform utilizing sublingual thin film strip technology. The company's flagship product, QuickStrip™, is a fast-dissolving system designed for the rapid release of pharmaceuticals, micronized oils, and over-the-counter medicines. QuickStrip™ is distinguished by its ability to achieve blood concentrations comparable to intravenous injection, offering superior bioavailability and rapid onset. RDT provides product innovation, production, and consultation services to the pharmaceutical and healthcare manufacturing sectors for both prescription and non-prescription applications.

Recent filings

Filing Released Lang Actions
Business acquisition report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a Form 51-102F4, which is a specific regulatory form used in Canadian securities regulation to disclose details of a business acquisition. The content focuses on the acquisition details, including the nature of the business acquired, acquisition date, consideration, and effect on financial position. It does not contain full financial statements or comprehensive financial performance data, nor is it an announcement of voting results, management changes, or other categories. It is a detailed disclosure about a capital transaction (acquisition) and thus fits best under Capital/Financing Update (CAP). The document length is short and focused on acquisition details, not a full annual or interim report or audit report. Therefore, the classification is CAP with high confidence.
2023-02-10 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Rapid Dose Therapeutics Reports Quarterly Financial Results for First Three Quarters of the 2023 Fiscal Year' and contains detailed quarterly financial data for three quarters of 2022, including revenue, operating expenses, net loss, and shares outstanding. It also discusses operational highlights for each quarter and references the filing of audited financial statements for the fiscal year ended February 28, 2022. The document is approximately 7,496 characters long, which is sufficient to contain substantive financial data and analysis. The content is consistent with a comprehensive interim or quarterly financial report rather than a brief earnings release or an announcement of a report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2023
2023-02-01 English
News release - English.pdf
Annual Report Classification · 95% confidence The document is a detailed announcement of Rapid Dose Therapeutics Corp.'s fiscal year 2022 financial results, including restated revenue figures, impairment charges, operational highlights, and forward-looking statements. It references the filing of audited financial statements for the fiscal year ended February 28, 2022, and interim financial statements for subsequent quarters. The document contains substantive financial data such as revenue, operating expenses, net loss, and share counts, as well as detailed operational and strategic information. It is not merely an announcement of a report being published or attached, but provides actual financial results and analysis. Therefore, it fits the definition of an Annual Report (10-K) or equivalent comprehensive yearly financial report. Given the fiscal year focus and detailed financial and operational data, the appropriate classification is Annual Report (10-K). FY 2022
2023-02-01 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 13-502F1 submission to the Ontario Securities Commission, which is a regulatory filing related to participation fees for Class 1 and Class 3B reporting issuers. It contains a management certification by the CEO, Mark Upsdell, certifying the accuracy of the information. The content includes detailed market value calculations for specified trading periods, capitalization, and fee calculations. There are no financial statements, earnings data, or management discussion of financial results. The document is primarily a regulatory compliance filing with certification, not a financial report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS).
2023-01-31 English
Interim MD&A (amended) - English.pdf
Management Reports Classification · 100% confidence The document is titled 'Management’s Discussion and Analysis May 31, 2022' and contains detailed discussion and analysis of the company's financial condition and results of operations for the three months ended May 31, 2022. It references unaudited condensed interim consolidated financial statements and is prepared in accordance with International Accounting Standard 34, which pertains to interim financial reporting. The document includes forward-looking statements, business overview, and detailed operational and financial commentary typical of an MD&A section. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a full report, not merely an announcement or certification. Therefore, this document fits the definition of a Management Reports (MDA) filing.
2023-01-30 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2023-01-30 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.